Recombinant Human TNFRSF18 Protein, His-tagged
Cat.No. : | TNFRSF18-2769H |
Product Overview : | Recombinant Human TNFRSF18 Protein (Leu39-Val152) with a N-His tag was expressed in E. coli. |
- Specification
- Gene Information
- Related Products
- Download
Description : | This gene encodes a member of the TNF-receptor superfamily. The encoded receptor has been shown to have increased expression upon T-cell activation, and it is thought to play a key role in dominant immunological self-tolerance maintained by CD25(+)CD4(+) regulatory T cells. Knockout studies in mice also suggest the role of this receptor is in the regulation of CD3-driven T-cell activation and programmed cell death. Three alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. |
Source : | E. coli |
Species : | Human |
Tag : | His |
Form : | Freeze-dried powder |
Molecular Mass : | Predicted Molecular Mass: 12.5 kDa |
Protein length : | Leu39-Val152 |
Endotoxin : | <1.0 EU per 1µg (determined by the LAL method). |
Purity : | > 97% |
Applications : | Positive Control; Immunogen; SDS-PAGE; WB. |
Stability : | The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 centigrade for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition. |
Storage : | Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months. |
Storage Buffer : | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
Reconstitution : | Reconstitute in PBS or others. |
Gene Name : | TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Homo sapiens (human) ] |
Official Symbol : | TNFRSF18 |
Synonyms : | TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18; AITR; CD357; GITR; activation-inducible TNFR family receptor; glucocorticoid-induced TNFR-related protein; TNF receptor superfamily activation-inducible protein; GITR-D; |
Gene ID : | 8784 |
mRNA Refseq : | NM_004195 |
Protein Refseq : | NP_004186 |
MIM : | 603905 |
UniProt ID : | Q9Y5U5 |
Products Types
◆ Recombinant Protein | ||
TNFRSF18-664R | Recombinant Rat TNFRSF18 Protein | +Inquiry |
TNFRSF18-148H | Recombinant Human TNFRSF18 Protein, His (Fc)-Avi-tagged | +Inquiry |
Tnfrsf18-6547M | Recombinant Mouse Tnfrsf18 Protein, Myc/DDK-tagged | +Inquiry |
Tnfrsf18-2770M | Recombinant Mouse Tnfrsf18 Protein, His-tagged | +Inquiry |
TNFRSF18-1019C | Recombinant Cynomolgus TNFRSF18 Protein (Met1-Glu155), His-tagged | +Inquiry |
◆ Lysates | ||
TNFRSF18-1143HCL | Recombinant Human TNFRSF18 cell lysate | +Inquiry |
TNFRSF18-1245RCL | Recombinant Rat TNFRSF18 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThis flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.
Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.
The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.
Q&As (5)
Ask a questionClinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.
As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.
Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.
TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.
Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.
Ask a Question for All TNFRSF18 Products
Required fields are marked with *
My Review for All TNFRSF18 Products
Required fields are marked with *
Inquiry Basket